- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01664910
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: Methotrexate
- Biological: Rituximab
- Biological: Inotuzumab Ozogamicin
- Procedure: Allogeneic Bone Marrow Transplantation
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Biological: Anti-Thymocyte Globulin
- Drug: Bendamustine Hydrochloride
- Drug: Fludarabine Phosphate
- Procedure: Peripheral Blood Stem Cell Transplantation
- Drug: Tacrolimus
Detailed Description
PRIMARY OBJECTIVES:
I. To characterize the safety of anti-cluster of differentiation (CD) 22 immunoconjugate inotuzumab ozogamicin (CMC-544), when administered in conjunction with fludarabine (fludarabine phosphate), bendamustine (bendamustine hydrochloride), and rituximab as non-myeloablative preparative regimen for allogeneic stem cell transplantation for CD22-positive lymphoid malignancies.
SECONDARY OBJECTIVES:
I. To estimate tumor response. II. To determine overall and event-free survival rates by histology subtype.
OUTLINE: This is a dose-escalation study of inotuzumab ozogamicin.
Patients receive inotuzumab ozogamicin intravenously (IV) over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with matched unrelated donors (MUD) receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or orally (PO) daily beginning on days -2 to 180 followed by taper in the absence of graft-versus-host disease (GVHD) and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic bone marrow (BM) or peripheral blood stem cell (PBSC) transplant on day 0.
After completion of study treatment, patients are followed up periodically.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with B-cell hematological malignancies who are eligible for allogeneic transplantation
- Patients must have a fully-matched sibling donor or a matched unrelated donor identified
- Performance score of at least 80% by Karnofsky or 0 to 2 Eastern Cooperative Oncology Group (ECOG)
- Left ventricular ejection fraction (EF) >= 45% with no uncontrolled arrhythmias or symptomatic heart disease
- Forced expiratory volume in one second (FEV1) >= 50%
- Forced vital capacity (FVC) >= 50%
- Corrected diffusion capacity of the lung for carbon monoxide (DLCO) >= 50%
- Serum creatinine < 1.6 mg/dL
- Serum bilirubin < 2 mg/dL upper limit of normal (unless due to Gilbert's disease; patient with this disease should have a right upper quadrant ultrasound evaluation before treatment)
- Serum glutamate pyruvate transaminase (SGPT) < 2 x upper limit of normal
- Men and women of reproductive potential must agree to follow accepted birth control methods (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study
- Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential (defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding; pregnancy testing is not required for post-menopausal or surgically sterilized women
Exclusion Criteria:
- Patient with active central nervous system (CNS) involvement
- Known infection with human immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV)-I, hepatitis B, or hepatitis C
- Patients with other malignancies diagnosed within 2 years prior to study registration; skin squamous or basal cell carcinoma are exceptions
- Active bacterial, viral or fungal infections
- History of stroke within 6 months
- History of biliary colic attack
- A prior autologous transplant within 3 months of study entry or allogeneic stem cell transplant
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study
- Patient has received other investigational drugs within 3 weeks before study registration
- Serious nonmalignant disease which, in the opinion of the investigator would compromise protocol objectives
- Prior exposure to CMC-544 within past 6 months
- Established refractoriness to CMC-544
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (transplant)
Patients receive inotuzumab ozogamicin IV over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3.
Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with MUD receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1.
All patients also receive tacrolimus IV over 24 hours continuously or PO daily beginning on days -2 to 180 followed by taper in the absence of GVHD and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD).
Patients undergo allogeneic BM or PBSC transplant on day 0.
|
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo allogeneic BM transplant
Other Names:
Undergo allogeneic PBSC or BM transplant
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo allogeneic PBSC transplant
Other Names:
Given IV or PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum-tolerated dose (MTD) of inotuzumab ozogamicin
Time Frame: Up to 30 days
|
Defined as the highest dose for which the probability of toxicity is closest to 30%.
|
Up to 30 days
|
Incidence of dose-limiting toxicity
Time Frame: Up to 30 days
|
Defined as grade III or IV renal, hepatic, intestinal, neurologic, pulmonary or cardiac adverse events, as well as graft failure or death at any time.
|
Up to 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective overall response (complete remission and partial remission)
Time Frame: Up to 3 years
|
Estimated with a 95% confidence interval in the dose that is declared the MTD.
Logistic regression will be used to assess the association between response and disease and clinical characteristics of interest.
|
Up to 3 years
|
Overall survival (OS)
Time Frame: Up to 3 years
|
Kaplan-Meier survival curves will be used to estimate OS.
Cox proportional hazards regression methodology will be used to assess the association between disease and clinical characteristics and the survival outcomes.
|
Up to 3 years
|
Recurrence-free survival
Time Frame: Up to 3 years
|
Kaplan-Meier survival curves will be used to estimate recurrence-free survival.
Cox proportional hazards regression methodology will be used to assess the association between disease and clinical characteristics and the survival outcomes.
|
Up to 3 years
|
Cumulative incidence of acute and chronic graft versus host disease (GVHD)
Time Frame: Up to 3 years
|
The method of Gooley et al will be used to estimate the cumulative incidence of acute and chronic GVHD.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Issa Khouri, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Hematologic Diseases
- Hematologic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Dermatologic Agents
- Antibiotics, Antineoplastic
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Calcineurin Inhibitors
- Immunoconjugates
- Immunotoxins
- Antibodies
- Immunoglobulins
- Bendamustine Hydrochloride
- Rituximab
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Fludarabine
- Fludarabine phosphate
- Methotrexate
- Tacrolimus
- Thymoglobulin
- Antilymphocyte Serum
- Inotuzumab Ozogamicin
Other Study ID Numbers
- 2012-0265 (Other Identifier: M D Anderson Cancer Center)
- NCI-2012-02072 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm
-
University of California, San FranciscoLazarex Cancer FoundationTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
Clinical Trials on Methotrexate
-
University Hospital, MontpellierPfizer; Hôpital CochinCompletedRheumatoid ArthritisFrance, Monaco
-
Nicolaus Copernicus UniversityCompleted
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Unknown
-
Hee Young JuNot yet recruitingLymphoblastic Leukemia in Children
-
PfizerCompletedRheumatoid ArthritisUnited States, Mexico, Argentina, Chile, Croatia, Czech Republic, Hungary, Poland, Puerto Rico
-
PfizerCompletedRhematoid ArthritisSpain, United Kingdom, United States, Korea, Republic of, Poland, Israel, Australia, Taiwan, Thailand, South Africa, Bulgaria, Estonia, Latvia, Philippines, Canada, Romania, Russian Federation, Turkey, Mexico, Bosnia and Herzegovina and more
-
Cairo UniversityCompleted
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
-
CHA UniversityCompleted
-
Mitsubishi Tanabe Pharma CorporationCompleted